AU2001246388A1 - Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine - Google Patents

Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine

Info

Publication number
AU2001246388A1
AU2001246388A1 AU2001246388A AU4638801A AU2001246388A1 AU 2001246388 A1 AU2001246388 A1 AU 2001246388A1 AU 2001246388 A AU2001246388 A AU 2001246388A AU 4638801 A AU4638801 A AU 4638801A AU 2001246388 A1 AU2001246388 A1 AU 2001246388A1
Authority
AU
Australia
Prior art keywords
desglymidodrine
midodrine
controlled release
release pharmaceutical
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246388A
Other languages
English (en)
Inventor
Poul Bertelsen
Peder Mohr Olsen
Annette Skinhoj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Austria GmbH
Original Assignee
Nycomed Danmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark AS filed Critical Nycomed Danmark AS
Publication of AU2001246388A1 publication Critical patent/AU2001246388A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001246388A 2000-03-31 2001-03-29 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine Abandoned AU2001246388A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000549 2000-03-31
DKPA200000549 2000-03-31
US20378300P 2000-05-12 2000-05-12
US60203783 2000-05-12
PCT/DK2001/000213 WO2001074334A1 (en) 2000-03-31 2001-03-29 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine

Publications (1)

Publication Number Publication Date
AU2001246388A1 true AU2001246388A1 (en) 2001-10-15

Family

ID=26068806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246388A Abandoned AU2001246388A1 (en) 2000-03-31 2001-03-29 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine

Country Status (10)

Country Link
EP (1) EP1267841B1 (de)
JP (1) JP2003528909A (de)
CN (1) CN1422150A (de)
AT (1) ATE283036T1 (de)
AU (1) AU2001246388A1 (de)
CA (1) CA2403886A1 (de)
DE (1) DE60107399D1 (de)
EE (1) EE200200556A (de)
NO (1) NO20024673L (de)
WO (1) WO2001074334A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089473A1 (en) * 2000-05-26 2001-11-29 Nycomed Austria Gmbh Pharmaceutical compositions comprising desglymidodrine as an active drug substance
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3518910A4 (de) * 2016-09-30 2020-11-04 Xenamed Corporation Midodrinzusammensetzungen und verfahren zur verwendung davon
AU2017346267A1 (en) * 2016-10-21 2019-05-16 Cellvertics Co., Ltd. Pharmaceutical composition for preventing or treating diabetes and/or hyperlipidemia comprising midorine or pharmaceutically acceptable salt thereof as active ingredient
US11013702B2 (en) 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
US20200338025A1 (en) * 2017-12-22 2020-10-29 Xenamed Corp. Extended release midodrine hydrochloride compositions and methods of use
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
KR102151051B1 (ko) * 2019-01-10 2020-09-02 고려대학교 산학협력단 당뇨병성 백내장 치료 또는 예방용 조성물
WO2022157633A1 (en) * 2021-01-20 2022-07-28 Cadila Healthcare Limited Enantiomerically pure desglymidodrine and process for preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3417576A1 (de) * 1984-05-11 1985-11-14 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Retardformen des alpha-(2,5-dimethoxy-phenyl)-ss-glycinamidoaethanols und verfahren zu ihrer herstellung
AT383270B (de) * 1984-05-15 1987-06-10 Chemie Linz Ag Verfahren zur herstellung von oralen retardformen des alpha-(2,5-dimethoxy-phenyl)-betaglycinamido|thanols
EP0423484B1 (de) * 1989-10-16 1993-11-03 PCD-Polymere Gesellschaft m.b.H. Pressling mit retardierter Wirkstofffreisetzung

Also Published As

Publication number Publication date
DE60107399D1 (de) 2004-12-30
CA2403886A1 (en) 2001-10-11
CN1422150A (zh) 2003-06-04
NO20024673D0 (no) 2002-09-30
ATE283036T1 (de) 2004-12-15
EP1267841A1 (de) 2003-01-02
NO20024673L (no) 2002-11-27
EP1267841B1 (de) 2004-11-24
JP2003528909A (ja) 2003-09-30
EE200200556A (et) 2004-04-15
WO2001074334A1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
WO2003082853A8 (en) New compounds
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
EP2201947A3 (de) Verwendung von SAHA zur Behandlung von Mesotheliom
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2910494C (en) Insulin-oligomer conjugates, formulations and uses thereof
MXPA02011624A (es) Uso de una composicion de celecoxib para alivio rapido del dolor.
RS20090105A (en) Medicament compositions based on tiotropium salts and on salmetrol salts
NO20041059L (no) Kombinasjon av utvalgte opioder med muskarinantagonister for behandling av urininkontinens
HUP0202776A2 (hu) (+)-Tramadol, O-demetil-tramadol, (+)-O-demetil-tramadol, O-demetil-N-mono-demetil-tramadol, illetve (+)-O-demetil-N-mono-demetil-tramadol felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
AU2001246388A1 (en) Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine
WO2003047552A3 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
MXPA02009176A (es) Tratamiento combinado con factor de crecimiento de queratinocito e inhibidor del factor de crecimiento epidermico.
WO2002060533A3 (de) Betamimetika enthaltende arzneimittelkompositionen mit geringere n nebenwirkungen
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
HK1058621A1 (en) Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
HUP0302984A2 (hu) Buprenorphin felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására